ARB combination therapy may increase risk of kidney failure.

This scholarly study, by researchers from the University of Alberta and the University of Calgary, sought to determine the safety of combination therapy of ACE inhibitors and ARB in the scientific setting as some randomized trials show an increased threat of kidney failure. Randomized trials may over or underestimate the risk of adverse events possibly due to patient selection bias, higher drug dosages and increased monitoring. Related StoriesAngiography and MPI: an interview with Professor Mauro Magnani University of UrbinoWhy do we rest? An interview with Professor WisdenDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixThe researchers looked at 32 312 seniors in Alberta, Canada, aged 65 and old who were prescribed an ACE inhibitor and/or an ARB.Jarnagin, M.D.: Pasireotide for Postoperative Pancreatic Fistula Although mortality after pancreatectomy has reduced to approximately 2 percent at high-volume centers, the operative morbidity after these procedures has remained between 30 percent and 50 percent.1,2 Postoperative pancreatic fistula, leak, and abscess are problems that derive from leakage of pancreatic exocrine secretions at the anastomosis or closure of the pancreatic remnant. Postoperative pancreatic fistula may be the most common major complication after pancreatectomy, with reported rates between 10 percent and 28 percent. Studies claim that individuals in whom postoperative pancreatic fistula develops have got a threat of death that’s approximately doubled.3,4 Because of the magnitude of this problem, numerous research have investigated options for reducing the risk of postoperative pancreatic fistula.